SCHEMBL4292455

SCHEMBL4292455

CCCCCC=CCC=CCC=CCC=CCCC(C(=O)O)c1cc2ccc(O)cc2oc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 6/20 0.42
▸ PFKFB3 Q16875 1/20 0.42
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MAPT P10636 3/20 0.41
▸ GLA P06280 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ S1PR4 O95977 1/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ HSD17B3 P37058 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ HPGD P15428 3/20 0.41
▸ THRB P10828 1/20 0.41
▸ CNR1 P21554 2/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ PSMB11 A5LHX3 1/20 0.39
▸ PSMA7 O14818 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4292441 0.80 MIF (0.42) MIFPFKFB3MEN1KMT2AMAPT
SCHEMBL18422152 0.78 ELANE (0.46) MIFPFKFB3MEN1KMT2AMAPT
SCHEMBL18423283 0.78 ELANE (0.46) MIFPFKFB3MEN1KMT2AMAPT
Arachidonic Acid SCHEMBL28529406 0.74 ALDH1A1 (0.56) MEN1KMT2AMAPTGLAKDM4E
SCHEMBL592464 0.72 HSD17B3 (0.49) MIFPFKFB3MEN1KMT2AMAPT
SCHEMBL9436011 0.71 MIF (0.60) MIFPFKFB3MEN1KMT2AMAPT
SCHEMBL4303187 0.69 POLB (0.43) MIFMEN1KMT2AMAPTGLA
SCHEMBL3958792 0.69 NDUFS8 (0.45) KDM4EALDH1A1MAOB
SCHEMBL4292453 0.69 POLB (0.43) MIFMEN1KMT2AMAPTGLA
SCHEMBL2886569 0.69 EPHX2 (0.45) MIFMEN1KMT2AMAPTGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090311723-A1 FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING WYETH (US) 2009-12-17 — — US claimed
US-20090311723-A1 FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING WYETH (US) 2009-12-17 — — US disclosed
US-20090311723-A1 FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING WYETH (US) 2009-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090311723-A1 FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING MGLL, LIPC, LIPA MIF 1210/4885PFKFB3 1636/4885MEN1 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback